Chargement en cours...
Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience
Sorafenib is an oral multitargeted tyrosine and serine/threonine kinase inhibitor approved for the treatment of advanced renal cell and hepatocellular carcinoma. An understanding of its dose–toxicity relationship has paved the way for trials seeking to enhance its clinical activity through the explo...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2011
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3126039/ https://ncbi.nlm.nih.gov/pubmed/21789159 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834010396117 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|